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Education in Human Research 
Protection 
 
Sarah Fowler-Dixon, PhD 
Education Specialist 
2003 
Defining Clinical Trials 
Today’s Agenda 
Specifically define what activities fall under 
“clinical trial” 
Discuss the ethics associated with clinical 
trials 
– Explain how the HSC handles these 
dilemmas 
Research studies designed to answer 
specific questions about vaccines, new 
therapies, new drugs, or new treatment 
methods. 
Also known as: medical research and 
research studies 
Clinical Trials Are: 
What is “Research?” 
Patient-oriented research 
– Conducted with human subjects or on 
material of human origin  
Excluded: in vitro experiments with material 
that cannot be linked to a living individual. 
Epidemiologic and behavioral studies;  
Outcomes research and health 
services research. 
 













When are “Human Subjects” 
involved? 




IRB submission.  





Types of Human Subjects 
Healthy volunteers 
Patients with a specified disease 
– Risk category for these patients may be different than 
for healthy people – their daily experiences are 
different. 
Vulnerable populations 
– Minors, pregnant women, cognitively impaired, 
prisoners, students 
– Additional regulations apply. 
Third parties 
 
Types of Interactions/Interventions 
Minimal Risk 
 Probability and magnitude of harm or 
discomfort anticipated in the research are 
not greater in and of themselves than 
those ordinarily encountered in daily life or 
during the performance of routine physical 
or psychological examinations or tests 
Greater than Minimal Risk 
Risk Category 
Affects frequency of review, consent 
requirements, remuneration amount, and who 
can be involved. 
Sources of risk: 
– The intervention itself  
unproven drug/device 
Uncomfortable survey 
– Surgery or other drugs associated with the 
investigational intervention 
– Loss of confidentiality 
– Production of sensitive data (HIV status, genetic 
information, criminal activity, etc) 
 
not FDA approved 
FDA approved but trying to obtain a 
new drug label indication 
4 Phases 
– Phase I :  Safety (Healthy participants) 
– Phase II:  Effectiveness  
– Phase III:  Standard of care comparison 
– Phase IV:  Marketing 
Types of Clinical Trials: 
Investigational Drugs 
Class 1 - General Controls 
– general controls that apply to all devices 
Class II  - Special Controls 
– additional controls needed to ensure safety 
and effectiveness 
Class III - Premarket Approval 
– Implanted and life-supported or life-
sustaining devices 
– need FDA approval for safety and 
effectiveness 
Device Classifications 









NIH and other federal agencies 
Departments or individual investigators 
Medical device or equipment developers 
Health care institutions such as HMOs 
 
Considerations about sponsors: 
– Multi-site? 
– Financial conflict of interest 
Who Sponsors Trials? 
Federal codes 
– 45 CFR 46: DHHS Common Rule 
– 21 CFR 50: FDA Protection of Human Subjects 
Ethical codes 
– Nuremberg Code 
– Declaration of Helsinki (October 2000) 
– Belmont Report 
International Council on Harmonization 
– Good Clinical Practice 
What governs clinical trials? 
1947:  Nuremburg Code 
Experiments in 
concentration 





trial of Nazi 
officials. 
1. Informed consent 
2. Fruitful results for good of 
society 
3. Based on previous animal 
experiments 
4. Minimize risk; risk/benefit ratio 
5. No experiments where death 
is expected 
6. Investigators qualified 
7. Subject free to leave study at 
any time 
1964 Declaration of Helsinki 
By World Medical Association (WMA); 
international code 
Revised five times, most recently in 
2000; most current ethical code 
“Provides guidance to physicians and 
other  participants in medical research 
involving human subjects.” - DoH 
2002 
– PI responsible for trial conduct 
 
Declaration of Helsinki 
“The health of my patient will be my first 
consideration.” 
“…considerations related to the well-
being of the human subject should take 
precedence over the interests of 
science and society.” 
“Some research populations are 
vulnerable and need special protection.” 
1978 Belmont Report 
Published by the National Commission. 
Principles for guiding research review: 
Respect for Persons: informed consent & 
vulnerable populations 
Beneficence: minimizing risk, risks vs 
benefits 
Justice: equitable subject selection, fair 
distribution of benefits and burdens 
 
Research Ethics 101  
Design and performance be clearly 
formulated and conform to generally 
accepted scientific principles 
– protocol:  background, objectives,  inclusion/exclusion 
criteria, treatment plan, follow-up procedures 
– informed consent document 
A statement of ethical considerations 
should be included 
– purpose section of informed consent 
document 
– protocol 
Research Ethics 101  
Only scientifically qualified persons 
should conduct the research 
– Human Studies Training Module 
Risk/Benefit analysis should be 
conducted 
– protocol and informed consent document 
Informed consent of study volunteers 
– 8 elements of informed consent 
– no finder’s fees 
– waivers and modifications of consent 
 
Research Ethics 101 
Special considerations for consenting 
minors and cognitively impaired 
– assent 7 and older 
– legal authorized representative 
Ability to withdraw or refuse 





Research Ethics 102: 
Additional Principles 
“When medical research is combined with 
medical care, additional standards apply to 
protect the patients who are research 
subjects” 
Comparison with current methods should 
take place 
Patients should have access to methods 
once study is complete. 
Research Ethics 102: 
Additional Principles 
Patient should be told which treatments 
are related to research. 
If no proven treatments, drugs, therapies 
exist, unproven measures may be used 
with patient consent. 
Unsolved Mysteries 
Placebo vs. existing treatment 
– availability of products 
– research questions differ among populations 
Studies with more narrowed focuses 
– public health, epidemiological, social, behavioral 
research not encompassed by DoH 
“Best method” determination 
– takes more than one clinical trial 
Limited representation of patients, persons 
from developing countries, women 





The Human Studies Committee 
– Initial review of every study; subsequent 
review dependent on type of study and risk 
involved 
– Mandatory investigator education 
